Keros Therapeutics (KROS) Receivables - Other (2019 - 2020)

Keros Therapeutics (KROS) posted Receivables - Other of $805000.0 for Q1 2020, down 10.56% on a QoQ basis from $900000.0 in Q4 2019.

Keros Therapeutics (KROS) Receivables - Other (2019 - 2020) Analysis & Trends

Keros Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $805000.0 for Q1 2020.

Quarterly Receivables - Other changed N/A year-over-year to $805000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $805000.0 (changed N/A YoY) and the FY2019 annual result came in at $900000.0, changed N/A from the prior year.
Receivables - Other was $805000.0 for Q1 2020 at Keros Therapeutics, down from $900000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $900000.0 in Q4 2019 and bottomed at $805000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Keros Therapeutics	377.42 Mn	90.02 Mn	-

Download Data